Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

When new data for anamorelin were presented at a large European meeting in 2014, oncology experts enthusiastically welcomed them, and hopes were raised that there may at last be a drug for cancer ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients with ...